HippoFi (OTC: ORHB) is a leading health care technology company and authority in spinal biologics, focused on the development and distribution of innovative biotech products. The company today announced that, over the last six months, while under a confidential letter of intent (“LOI”) in a strategic partnership, it has designed and formulated a strategic launch of the PURmarrow 360 bone marrow aspirate (“BMA”) device throughout the United States. The product is a natural extension to HippoFi’s robust product line, allowing surgeons to selectively capture highly desired cells from a patient’s own BMA during surgery. The rich marrow enhances the effectiveness of PUR’s products by combining stem cells, growth factors and proteins, helping to supercharge bone growth in spine surgeries and improve patient healing. “As a market leader in innovation, we believe PURmarrow 360 is in the patient’s best interest, as the purity and genetic makeup of their own living cells is unmatched,” said CJ Wiggins, executive chairman and CEO of HippoFi. “PURmarrow 360 is simple to use, without requiring centrifugation, making it easy for spine surgeons to incorporate in every spine surgery.”
In addition, the company announced its entry into the final phase of negotiations for definitive agreements as part of the confidential LOI with a highly respected industry leader. HippoFi plans to soon announce the intended long-term strategic relationship, which will leverage the extensive expertise of both companies to create a breakthrough biomaterial that has already shown promise to be a game-changing solution for bone growth. “The companies will work together with the intent of near-term product commercialization to bring this new technology to health care providers and help improve patient’s functional outcomes,” Wiggins said of the collaboration.
To view the full press releases, visit https://ibn.fm/xZcGC and https://ibn.fm/6vWUM
About HippoFi Inc.
HippoFi delivers its cutting-edge health care innovations and propriety technologies through an extensive sales channel network, while implementing first-to-market solutions in the multibillion-dollar biotech, fintech and artificial intelligence (“AI”) markets. HippoFi comprises three segments: regenerative therapeutics, digital payments and AI, and utilizes the same customer channels to commercialize solutions, drive revenue and improve patient outcomes. HippoFi is publicly traded under the symbol ORHB and is headquartered in Irvine, California, USA. For more information, visit www.HippoFi.com and www.PURbiologics.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
